Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/6/2025

Management of Hypertension in CKD Stage 5

Introduction to Hypertension Management

  • The Kidney International guideline recommends considering reducing the dose or discontinuing ACE inhibitors or ARBs to manage symptomatic hypotension, uncontrolled hyperkalemia despite medical treatment, or to reduce uremic symptoms while treating kidney failure in patients with CKD Stage 5 (eGFR <15 mL/min/1.73 m²) 1

Blood Pressure Target

  • The Kidney International guideline recommends targeting systolic BP <120 mmHg when tolerated using standardized office BP measurement, with an alternative acceptable systolic BP range of 130-139 mmHg 2, 1, 3
  • The European Heart Journal suggests that a systolic BP range of 130-139 mmHg is acceptable 3

First-Line Antihypertensive Agents

  • The Kidney International guideline recommends administering ACE inhibitors or ARBs at the highest approved dose that is tolerated, as proven benefits were achieved in trials using these doses 4, 1

Monitoring Parameters for RAS Inhibitors

  • The Kidney International guideline recommends checking serum creatinine and potassium within 2-4 weeks of initiation or dose increase of RAS inhibitors 4, 1, 5
  • The Kidney International guideline suggests continuing therapy if creatinine rises ≤30% within 4 weeks, as this reflects hemodynamic changes and does not indicate harm 1, 5

Second-Line and Additional Agents

  • The Praxis Medical Insights guideline recommends using loop diuretics when GFR <30 mL/min or serum creatinine >2.0 mg/dL, as thiazides become ineffective 5
  • The Kidney International guideline recommends using dihydropyridine CCBs (e.g., amlodipine, nifedipine) as second-line therapy 5

Management of Hyperkalemia

  • The Kidney International guideline recommends managing hyperkalemia associated with RAS inhibitors by measures to reduce serum potassium levels rather than decreasing the dose or stopping the RAS inhibitor 4, 1

Contraindicated Combinations

  • The Kidney International guideline recommends never combining ACE inhibitor + ARB + direct renin inhibitor, as this triple combination increases adverse events without benefit 4, 1, 6

Non-Pharmacological Management

  • The Praxis Medical Insights guideline recommends restricting dietary sodium to <2.0 g/day (<90 mmol/day) to enhance diuretic efficacy and BP control 5
  • The American Journal of Kidney Diseases recommends reducing dietary sodium to 2.3 g/day to optimize medication effectiveness 7, 8

Typical Multi-Drug Regimen

  • The American Journal of Kidney Diseases recommends using a typical multi-drug regimen consisting of ACE inhibitor or ARB, loop diuretic, and dihydropyridine CCB to achieve BP control in CKD Stage 5 patients 7, 8

Common Pitfalls to Avoid

  • The Kidney International guideline recommends not stopping ACE inhibitor/ARB for modest creatinine increases up to 30% 1, 5
  • The Praxis Medical Insights guideline recommends not using thiazide diuretics as monotherapy in Stage 5 CKD, as they are ineffective 5
  • The Kidney International guideline recommends not applying intensive BP targets (<120 mmHg) to non-standardized BP measurements 1

REFERENCES

5

Blood Pressure Management in Renal Failure [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

← Return to Home